Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Short Interest Update

Invesco Pharmaceuticals ETF (NYSEARCA:PJP) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totaling 6,940 shares, a decrease of 56.3% from the December 15th total of 15,881 shares. Based on an average daily trading volume, of 15,806 shares, the short-interest ratio is currently 0.4 days. Approximately 0.2% of the company’s shares are sold short. Approximately 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 15,806 shares, the short-interest ratio is currently 0.4 days.

Invesco Pharmaceuticals ETF Stock Performance

NYSEARCA:PJP traded up $0.93 on Wednesday, reaching $105.69. The company’s stock had a trading volume of 16,835 shares, compared to its average volume of 154,593. Invesco Pharmaceuticals ETF has a 1-year low of $72.25 and a 1-year high of $108.40. The business’s 50-day moving average price is $104.72 and its two-hundred day moving average price is $94.81. The firm has a market cap of $329.75 million, a PE ratio of 15.59 and a beta of 0.50.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Peak Asset Management LLC increased its position in shares of Invesco Pharmaceuticals ETF by 2.5% during the second quarter. Peak Asset Management LLC now owns 136,156 shares of the company’s stock worth $10,875,000 after acquiring an additional 3,339 shares in the last quarter. Joseph Group Capital Management boosted its position in shares of Invesco Pharmaceuticals ETF by 4.2% during the third quarter. Joseph Group Capital Management now owns 22,131 shares of the company’s stock worth $2,047,000 after buying an additional 889 shares during the period. Envestnet Asset Management Inc. boosted its position in Invesco Pharmaceuticals ETF by 5.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 19,547 shares of the company’s stock worth $1,561,000 after acquiring an additional 1,040 shares during the last quarter. Trilogy Capital Inc. bought a new stake in shares of Invesco Pharmaceuticals ETF in the second quarter worth $1,330,000. Finally, Ameriprise Financial Inc. boosted its holdings in Invesco Pharmaceuticals ETF by 214.4% during the third quarter. Ameriprise Financial Inc. now owns 12,236 shares of the company’s stock worth $1,114,000 after purchasing an additional 8,344 shares during the last quarter.

Invesco Pharmaceuticals ETF Company Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.